Compare Abbott Laboratories (ABT) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Air Products & Chemicals, Inc. — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Air Products & Chemicals, Inc. trades at $297.93 (market cap $67.93B). The key difference: Abbott Laboratories is far larger — about 2.5× Air Products & Chemicals, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | APD | |
|---|---|---|
Market Cap | $166.94B | $67.93B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $314.19 |
52-Week Low | $82.57 | $230.42 |
Enterprise Value | $193.69B | $85.34B |
Dividend Yield | 2.63% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
APD trades at $305.05, down 2.91% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, though 2025 saw a net loss of $394.50 million. Recent strategic moves include exiting the Louisiana Clean Energy Complex and finalizing a renewable ammonia deal with Yara, signaling a refined growth focus.
The outlook is positive with a consensus price target of $324.89, implying 6.5% upside. Risks include high debt levels and volatile cash flows from heavy investments. Investors should weigh the company's long-term growth projects against near-term financial pressures and geopolitical uncertainties affecting supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
